<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>Avicenna Research Institute</PublisherName>
				<JournalTitle>Avicenna Journal of Medical Biotechnology</JournalTitle>
				<Issn>2008-2835</Issn>
				<Volume>18</Volume>
				<Issue>4</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>10</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Production of a Versatile Pan-DENV NS5 Polyclonal Antibody and Structural Epitope Analysis of Immunogen Performance</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>268</FirstPage>
			<LastPage>283</LastPage>
			<ELocationID EIdType="pii">254805</ELocationID>
			
<ELocationID EIdType="doi">10.18502/ajmb.v18i4.22925</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Liliana</FirstName>
					<LastName>Morales</LastName>
<Affiliation>Universidad El Bosque, Vicerrectoría de Investigaciones, Instituto de Biología Molecular, Laboratorio de  Parasitología Molecular, Bogotá, Colombia</Affiliation>
<Identifier Source="ORCID">0000-0002-0906-5383</Identifier>

</Author>
<Author>
					<FirstName>Claudia</FirstName>
					<LastName>Bueno-Angarita</LastName>

						<AffiliationInfo>
						<Affiliation>Universidad El Bosque, Vicerrectoría de Investigaciones, Instituto de Biología Molecular, Laboratorio de 
Parasitología Molecular, Bogotá, Colombia</Affiliation>
						</AffiliationInfo>

						<AffiliationInfo>
						<Affiliation>Universidad El Bosque, Vicerrectoría de Investigaciones, Grupo de Virología, Bogotá, Colombia</Affiliation>
						</AffiliationInfo>
<Identifier Source="ORCID">0000-0002-7628-8499</Identifier>

</Author>
<Author>
					<FirstName>María Angélica</FirstName>
					<LastName>Calderón-Peláez</LastName>
<Affiliation>Universidad El Bosque, Vicerrectoría de Investigaciones, Grupo de Virología, Bogotá, Colombia</Affiliation>
<Identifier Source="ORCID">0000-0003-0788-0795</Identifier>

</Author>
<Author>
					<FirstName>Myriam L.</FirstName>
					<LastName>Velandia-Romero</LastName>
<Affiliation>Universidad El Bosque, Vicerrectoría de Investigaciones, Grupo de Virología, Bogotá, Colombia</Affiliation>
<Identifier Source="ORCID">0000-0002-3340-7304</Identifier>

</Author>
<Author>
					<FirstName>Jaime E.</FirstName>
					<LastName>Castellanos</LastName>
<Affiliation>Universidad El Bosque, Vicerrectoría de Investigaciones, Grupo de Virología, Bogotá, Colombia</Affiliation>
<Identifier Source="ORCID">0000-0003-1596-8383</Identifier>

</Author>
<Author>
					<FirstName>Jacqueline</FirstName>
					<LastName>Chaparro-Olaya</LastName>
<Affiliation>Universidad El Bosque, Vicerrectoría de Investigaciones, Instituto de Biología Molecular, Laboratorio de 
Parasitología Molecular, Bogotá, Colombia</Affiliation>
<Identifier Source="ORCID">0000-0001-9815-3459</Identifier>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2026</Year>
					<Month>06</Month>
					<Day>13</Day>
				</PubDate>
			</History>
		    <Abstract>Background: Dengue is a major mosquito-borne viral disease worldwide, with approximately 400 million infections reported annually and no fully effective antiviral treatments available. The non-structural protein NS5 is a promising antiviral target due to its critical role in viral RNA replication and host interactions. Although commercial monoclonal and polyclonal anti-NS5 antibodies are available, none were found to combine broad reactivity against all four dengue virus serotypes with suitability for Western Blot (WB), Immunofluorescence (IF), and Immunoprecipitation (IP) assays. This study aimed to develop and functionally characterize a versatile polyclonal antibody targeting a conserved region of DENV NS5 for immunodetection applications. Methods: Conserved recombinant regions from the methyltransferase (MTase) and RNA-dependent RNA polymerase (RdRp) domains of DENV2 NS5 were expressed in Escherichia coli and used as immunogens in a murine model. Results: Both recombinant proteins exhibited predicted antigenic potential, but only the anti-NS5-RdRp antibody efficiently recognized native NS5 in infected cells. The resulting antibody detected NS5 from all four dengue serotypes in WB, with lower nonspecific background than a widely used commercial antibody. In addition, it proved effective in IF and IP assays in DENV1- and DENV2-infected cells, enabling co-immuno-precipitation of NS3, a known NS5 interactor. Retrospective structural epitope analyses suggested that the RdRp immunogen contained surface-accessible conformational features more compatible with antibody recognition in the native protein context. Conclusion: These findings identify the anti-NS5-RdRp antibody as a valuable tool for dengue research and illustrate how structural epitope analyses can provide insights into differences in immunogen performance.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">dengue virus</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Epitopes</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Recombinant Proteins</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.ajmb.org/article_254805_26fa5ac538112f81aaed69076aebfab6.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Avicenna Research Institute</PublisherName>
				<JournalTitle>Avicenna Journal of Medical Biotechnology</JournalTitle>
				<Issn>2008-2835</Issn>
				<Volume>18</Volume>
				<Issue>4</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>10</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Selective Induction of Apoptosis in Hepatocellular Carcinoma Cells by AFP Promoter-Driven Apoptin Expression: An In Vitro Gene Therapy Approach</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>284</FirstPage>
			<LastPage>293</LastPage>
			<ELocationID EIdType="pii">254814</ELocationID>
			
<ELocationID EIdType="doi">10.18502/ajmb.v18i4.22926</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Maryam</FirstName>
					<LastName>Bonyadi Fard</LastName>

						<AffiliationInfo>
						<Affiliation>Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran</Affiliation>
						</AffiliationInfo>

						<AffiliationInfo>
						<Affiliation>Department of Biology, Payame Noor University, Tehran, Iran</Affiliation>
						</AffiliationInfo>

</Author>
<Author>
					<FirstName>Hossein</FirstName>
					<LastName>Maghsoudi</LastName>
<Affiliation>Department of Biology, Payame Noor University, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Farahnaz</FirstName>
					<LastName>Zare</LastName>
<Affiliation>Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Gholamreza</FirstName>
					<LastName>Rafiei Dehbidi</LastName>
<Affiliation>Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Marzieh</FirstName>
					<LastName>Alizadeh Zarei</LastName>
<Affiliation>Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Abbas</FirstName>
					<LastName>Behzad Behbahani</LastName>
<Affiliation>Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2026</Year>
					<Month>06</Month>
					<Day>09</Day>
				</PubDate>
			</History>
		    <Abstract>Background: Hepatocellular Carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, and developing tumor-selective therapies with minimal off-target toxicity is a major challenge. Alpha-fetoprotein (AFP), which is highly expressed in HCC but absent in most normal adult hepatocytes, is a promising target for selective gene therapy. Apoptin, a viral protein, induces apoptosis preferentially in malignant cells.Methods: An AFP promoter-driven Apoptin expression construct was generated using the pAdenoVator-IRES-GFP vector and transiently transfected into HepG2 cells. Promoter specificity was evaluated in AFP-negative HeLa and LNCaP cells. Transfection efficiency was assessed by GFP fluorescence microscopy. Cell viability was measured by MTT assay, Apoptin mRNA expression by RT-qPCR, and apoptosis by Annexin V/7-AAD flow cytometry. Experiments were performed in triplicate.Results: GFP fluorescence was visibly stronger in HepG2 cells than in HeLa or LNCaP cells on qualitative microscopic examination, consistent with AFP promoter selectivity. AFP promoter-driven Apoptin expression significantly reduced HepG2 cell viability to 50.2%±4.3% of control levels (p=0.0317, n=3 independent experiments). RT-qPCR showed a significant increase in Apoptin mRNA expression in transfected HepG2 cells. Flow cytometry showed a significant increase in apoptosis, with approximately 20% more Annexin V-positive cells than controls (p=0.0286, n=3 independent experiments).Conclusion: AFP promoter-driven Apoptin expression selectively induced apoptosis and reduced viability in HCC cells in vitro. These findings highlight the potential of AFP promoter-based Apoptin gene therapy as a tumor-selective therapeutic approach for HCC and support further evaluation in preclinical models.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Alpha-fetoprotein</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Apoptin</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Apoptosis</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Genetic therapy</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Hepatocellular carcinoma</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.ajmb.org/article_254814_7d2c80c2b3190f163f1ae22e47fbdaec.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Avicenna Research Institute</PublisherName>
				<JournalTitle>Avicenna Journal of Medical Biotechnology</JournalTitle>
				<Issn>2008-2835</Issn>
				<Volume>18</Volume>
				<Issue>4</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>10</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Transcriptomic Analysis of EpCAM/CD45 Dual-Positive Ovarian Cancer Stem-Like Cells Reveals Inflammatory Signatures and Association with SYK</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>294</FirstPage>
			<LastPage>317</LastPage>
			<ELocationID EIdType="pii">254815</ELocationID>
			
<ELocationID EIdType="doi">10.18502/ajmb.v18i4.22927</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Mohammad Reza</FirstName>
					<LastName>Tayebizadeh-Meigooni</LastName>
<Affiliation>Department of Animal Biology, Developmental Biology Group, School of Biology, College of Science, University of Tehran, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Mahboubeh F</FirstName>
					<LastName>Safari Kharkeshi</LastName>
<Affiliation>Department of Animal Biology, Developmental Biology Group, School of Biology, College of Science, University of Tehran, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Sadra F</FirstName>
					<LastName>Daneshvari</LastName>
<Affiliation>Department of Animal Biology, Developmental Biology Group, School of Biology, College of Science, University of Tehran, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Ghamartaj</FirstName>
					<LastName>Hossein</LastName>
<Affiliation>Department of Animal Biology, Developmental Biology Group, School of Biology, College of Science, University of Tehran, Tehran, Iran</Affiliation>
<Identifier Source="ORCID">0000-0002-0034-5688</Identifier>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2026</Year>
					<Month>05</Month>
					<Day>30</Day>
				</PubDate>
			</History>
		    <Abstract>Background: Dual‑positive EpCAM⁺/CD45⁺ ovarian cancer cells in malignant ascites are proposed as ovarian cancer stem-like cells, yet their cellular origin and transcriptomic programs remain debated.Methods: In this work expression data from ascites‑derived EpCAM⁺/CD45⁺ dual‑positive ovarian cancer stem‑like cells (DpOCSCs; GSE75036) and reference non‑dual‑positive ovarian cancer stem cells (OCSCs; GSE90125, GSE216627) was integrated. The workflow included cross‑platform harmonization, differential expression analysis, pathway enrichment, protein–protein interaction mapping, and evaluation in independent cohorts (TCGA, CPTAC, survival databases).Results: DpOCSCs showed 347 up‑regulated and 23 down‑regulated genes (|log₂FC|&gt;1, FDR&lt;0.1). Enrichment analyses revealed overrepresentation of interferon‑α/γ responses, TNF, NF‑κB, IL‑6, JAK‑STAT3, and CXCR4 signaling, and pathways linked to natural killer cell‑mediated cytotoxicity, indicating a distinct inflammatory signature. Network analysis identified 17 up‑regulated hub genes; 10 had higher mRNA in ovarian tumors versus normal tissues (TCGA), and 3 (SYK, CD74, MX1) showed elevated protein in CPTAC. In bulk ovarian cancer cohorts, these hubs were exploratorily associated with copy‑number amplifications, immune‑checkpoint expression, immunosuppressive infiltration, and clinicopathological features, including lymphatic/venous invasion and therapy outcomes. Survival and ROC analyses indicated context‑dependent associations of SYK, CD74, and MX1 with overall and progression‑free survival; SYK achieved an AUC ≈0.7 for predicting 6‑month relapse, particularly in paclitaxel‑treated patients. Transcription‑factor enrichment implicated Wnt/β‑catenin, Hippo, and NF‑κB as upstream regulators.Conclusion: These in silico findings are hypothesis‑generating and nominate a SYK‑associated inflammatory network for functional assessment in DpOCSCs and as a potential source of exploratory biomarkers for recurrent ovarian cancer.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">gene expression profiling</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Interferons</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Neoplastic stem cells</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">ovarian neoplasms</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Protein interaction mapping</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">transcription factors</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.ajmb.org/article_254815_87949c9607f0bea9efab98cf662be060.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Avicenna Research Institute</PublisherName>
				<JournalTitle>Avicenna Journal of Medical Biotechnology</JournalTitle>
				<Issn>2008-2835</Issn>
				<Volume>18</Volume>
				<Issue>4</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>10</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Association of miR-326, SIRT1, and HMGA2 Expression in Breast Cancer Cells Exposed to Mesenchymal Stromal Cell-Derived Extracellular Vesicles</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>318</FirstPage>
			<LastPage>324</LastPage>
			<ELocationID EIdType="pii">254816</ELocationID>
			
<ELocationID EIdType="doi">10.18502/ajmb.v18i4.22928</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Mina</FirstName>
					<LastName>Ramezani</LastName>
<Affiliation>Department of Biology, Faculty of Science, Central Tehran Branch, Islamic Azad University</Affiliation>
<Identifier Source="ORCID">0000-0002-9547-0990</Identifier>

</Author>
<Author>
					<FirstName>Zeinab</FirstName>
					<LastName>Piravar</LastName>
<Affiliation>Department of Biology, Central Tehran Branch, Islamic Azad University, Imam Hasan Boulevard, Ponak Square</Affiliation>
<Identifier Source="ORCID">0000-0001-8949-362x</Identifier>

</Author>
<Author>
					<FirstName>Mahsa</FirstName>
					<LastName>Afradi Lamrasky</LastName>
<Affiliation>Department of Biology, Central Tehran Branch, Islamic Azad University, Imam Hasan Boulevard, Ponak Square</Affiliation>
<Identifier Source="ORCID">0009-0007-1134-5273</Identifier>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2026</Year>
					<Month>07</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		    <Abstract>Background: Breast cancer progression is influenced by tumor–microenvironment interactions mediated by Extracellular Vesicles (EVs), which transfer bioactive molecules such as microRNAs. This in vitro study investigated the role of miR-326 in modulating SIRT1 (Sirtuin 1) and HMGA2 (High-mobility group AT-hook 2) expression in breast cancer cells after treatment with EVs derived from Mesenchymal Stromal Cells (MSCs). Methods: EVs were isolated from MSCs using the ExoQuick kit and characterized by Dynamic Light Scattering (DLS). EV internalization was confirmed by PKH26 fluorescent staining. After determining the appropriate dose by MTT assay, EVs were applied to MDA-MB-231 cells. Expression levels of miR-326, SIRT1, and HMGA2 were measured by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR). GAPDH and U6 snRNA were used as internal reference genes for mRNA and miRNA normalization, respectively. Data were analyzed using the unpaired Student’s t-test.Results: The mean size of EVs was approximately 120 nm. The highest viability of MDA-MB-231 cells was observed at an EV dose of 30 µg/ml. Treatment with EVs caused a significant decrease in miR-326 expression (p&lt;0.05) and significant increases in the expression levels of SIRT1 (p&lt;0.01) and HMGA2 (p&lt;0.05).Conclusion: These findings suggest a potential association between miR-326 and its target genes, highlighting a possible therapeutic target within the tumor microenvironment.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Breast Neoplasms</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Dynamic Light Scattering</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Mesenchymal Stem Cells</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">MicroRNAs</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Polymerase Chain Reaction</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Sirtuin 1</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Tumor Microenvironment</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.ajmb.org/article_254816_6cf7e3557b70d78a7aee7751a2146146.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Avicenna Research Institute</PublisherName>
				<JournalTitle>Avicenna Journal of Medical Biotechnology</JournalTitle>
				<Issn>2008-2835</Issn>
				<Volume>18</Volume>
				<Issue>4</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>10</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>The Effect of Salmon DNA Polynucleotide on Cell Migration Percentage and the Expression of Collagen Type 1 (COL1A1) and Elastin (ELN) Genes in Injured Fibroblast Cell Lines</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>325</FirstPage>
			<LastPage>331</LastPage>
			<ELocationID EIdType="pii">254818</ELocationID>
			
<ELocationID EIdType="doi">10.18502/ajmb.v18i4.22929</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Mathelda</FirstName>
					<LastName>Weni</LastName>
<Affiliation>Faculty of Medicine, Maranatha Christian University, Bandung</Affiliation>

</Author>
<Author>
					<FirstName>Wahyu</FirstName>
					<LastName>Widowati</LastName>
<Affiliation>Faculty of Medicine, Maranatha Christian University, Bandung</Affiliation>
<Identifier Source="ORCID">0000-0002-5401-7794</Identifier>

</Author>
<Author>
					<FirstName>Meilinah</FirstName>
					<LastName>Hidayat</LastName>
<Affiliation>Faculty of Medicine, Maranatha Christian University, Bandung</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2026</Year>
					<Month>01</Month>
					<Day>07</Day>
				</PubDate>
			</History>
		    <Abstract>Background: People with sensitive skin often have compromised barrier function, hindering the wound healing process. Collagen and elastin are essential in all wound healing stages, from hemostasis to tissue remodeling. Salmon DNA polynucleotide (PN) is increasingly used in beauty clinics for sensitive skin indications due to its regenerative properties. This study aimed to explore the salmon-derived PN as anti-aging agent and its impact on wound healing in scratch-induced fibroblast cell cultures by evaluating cell migration and the expression of type I collagen (COL1A1) and elastin (ELN) genes. Methods: This study used BJ cell cultures from human skin fibroblasts. The cell migration was analyzed microscopically using ImageJ software, while COL1A1 and ELN expression were measured by qRT-PCR. Results: The IC50 of PN was 3.214%. The 0.78% PN concentration showed the highest cell migration, increasing by 33.80% at 48 hr post-scratch. PN also enhanced COL1A1 and ELN expression, with the most effective concentration among the tested concentrations observed at 0.78%. Conclusion: PN has been demonstrated to enhance fibroblast migration and increase COL1A1 and ELN gene expression in an in vitro scratch-injury model. Future studies to confirm these findings on experimental animals and human clinical trials are essential.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Cell migration</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">COL1A1</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">ELN</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Fibroblast</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Polynucleotide</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.ajmb.org/article_254818_a076cdc103e0ee52eed390d42090e785.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Avicenna Research Institute</PublisherName>
				<JournalTitle>Avicenna Journal of Medical Biotechnology</JournalTitle>
				<Issn>2008-2835</Issn>
				<Volume>18</Volume>
				<Issue>4</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>10</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>MF-59 Adjuvant vs. Alum in an Inactivated SARS-CoV-2 Vaccine Model: Focusing on Heterologous Antigen-Binding Response</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>332</FirstPage>
			<LastPage>340</LastPage>
			<ELocationID EIdType="pii">254819</ELocationID>
			
<ELocationID EIdType="doi">10.18502/ajmb.v18i4.22930</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Tadeh</FirstName>
					<LastName>Sepanian</LastName>
<Affiliation>Department of Immunology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Akbar</FirstName>
					<LastName>Khorasani</LastName>
<Affiliation>Department of FMD Vaccine Production, Razi Vaccine and Serum Research Institute, Agricultural Research Education and Extension Organization (AREEO), Karaj, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Bizhan</FirstName>
					<LastName>Sadighi Moghaddam</LastName>
<Affiliation>Department of Immunology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Rasoul</FirstName>
					<LastName>Baharlou</LastName>

						<AffiliationInfo>
						<Affiliation>Department of Immunology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran</Affiliation>
						</AffiliationInfo>

						<AffiliationInfo>
						<Affiliation>Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran</Affiliation>
						</AffiliationInfo>

</Author>
<Author>
					<FirstName>Mehdi</FirstName>
					<LastName>Mahdavi</LastName>

						<AffiliationInfo>
						<Affiliation>Advanced Therapy Medicinal Product (ATMP) Department, Breast Cancer Research Center, National Cancer   Institute, Academic Center for Education, Culture and Research (ACECR), Tehran, Iran</Affiliation>
						</AffiliationInfo>

						<AffiliationInfo>
						<Affiliation>Biotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran</Affiliation>
						</AffiliationInfo>
<Identifier Source="ORCID">0000-0003-4478-5957</Identifier>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2026</Year>
					<Month>05</Month>
					<Day>30</Day>
				</PubDate>
			</History>
		    <Abstract>Background: Clarifying the role of an adjuvant in vaccine formulation on the induction of a higher cross-reactivity response is very important in the vaccine formulation. In this study, the inactivated Wuhan-Hu-1 strain of SARS-CoV-2 virus was formulated in MF-59 and Alum adjuvants and the immunogenicity of these vaccines in the induction of cellular and humoral immune responses was assessed. In addition, the cross-binding IgG response Alpha variant (B.1.1.7) &quot;English variant&quot; was assessed by ELISA. Methods: Experimental BALB/c mice were immunized subcutaneously three times with MF-59- and Alum-based vaccines. Three weeks after the last immunization, lymphocyte proliferation of spleen cells was evaluated by BrdU method, and IL-4 and IFN-γ cytokines were assessed on the spleen cell culture supernatant by quantitative ELISA kits. In addition, specific total IgG and IgG1/IgG2a isotypes were assessed with an optimized indirect ELISA. Furthermore, the cross-binding IgG titer Alpha variant was assessed by ELISA. Results: The results showed that immunization with MF-59-inactivated SARS-CoV-2 vaccine led to a significant increase in lymphocyte proliferation, IFN-γ-associated responses, specific total IgG, and IgG1, and IgG2a isotypes compared with Alum group. In addition, inactivated SARS-CoV-2-MF59 vaccine revealed a numerically higher (70.83%) increase in the cross-binding IgG titer the inactivated SARS-CoV-2-Alum group.Conclusion: MF-59 could be used as a suitable adjuvant in SARS-CoV-2 vaccine development due to a better induction of IgG and IFN-γ responses than alum adjuvant and a higher induction of the cross-binding IgG response the Alpha variant. These findings showed that vaccine formulation is important in inducing cross-binding responses.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">adjuvant</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">T cell proliferation</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">IFN-g</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Heterologous IgG response</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Immunoglobulin G</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">SARS-CoV-2</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.ajmb.org/article_254819_fcbbd6c5f01644c85f8e29a01948c222.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Avicenna Research Institute</PublisherName>
				<JournalTitle>Avicenna Journal of Medical Biotechnology</JournalTitle>
				<Issn>2008-2835</Issn>
				<Volume>18</Volume>
				<Issue>4</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>10</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Newborn Screening for Inborn Metabolic Disorders in Iranian Infants: Comprehensive Evaluation of the Paya Hamsan Derivatized Technique for Tandem Mass Spectrometry</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>341</FirstPage>
			<LastPage>352</LastPage>
			<ELocationID EIdType="pii">254879</ELocationID>
			
<ELocationID EIdType="doi">10.18502/ajmb.v18i4.22931</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Azam</FirstName>
					<LastName>Khodadadi</LastName>
<Affiliation>Molecular Engineering &amp; Sciences Institute, Arak University, Arak, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Saber</FirstName>
					<LastName>Nanbedeh</LastName>
<Affiliation>Molecular Engineering &amp; Sciences Institute, Arak University, Arak, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Mahsa</FirstName>
					<LastName>Joodaki</LastName>
<Affiliation>Molecular Engineering &amp; Sciences Institute, Arak University, Arak, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Marjan</FirstName>
					<LastName>Esfahanizadeh</LastName>
<Affiliation>Central Research Laboratory, Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences,  Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Bradford L.</FirstName>
					<LastName>Therrell</LastName>

						<AffiliationInfo>
						<Affiliation>USA National Newborn Screening and Global Resource Center, Austin, Texas 78759, USA</Affiliation>
						</AffiliationInfo>

						<AffiliationInfo>
						<Affiliation>University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA</Affiliation>
						</AffiliationInfo>

</Author>
<Author>
					<FirstName>Kambiz</FirstName>
					<LastName>Gilany</LastName>

						<AffiliationInfo>
						<Affiliation>Reproductive Immunology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran</Affiliation>
						</AffiliationInfo>

						<AffiliationInfo>
						<Affiliation>Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran</Affiliation>
						</AffiliationInfo>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2026</Year>
					<Month>06</Month>
					<Day>28</Day>
				</PubDate>
			</History>
		    <Abstract>Background: Screening newborns for inborn metabolic disorders (IMDs) is important for early diagnosis and prevention of serious health complications. Tandem mass spectrometry (MS/MS) analysis of metabolites in dried blood spots (DBSs) has improved the accuracy and scope of neonatal screening. This study evaluated the performance of the Paya Hamsan Newborn Screening Derivatized (PH-NBS-D) MS/MS method for detecting and quantifying amino acids and acylcarnitines in newborns.Methods: The PH-NBS-D MS/MS assay was validated using DBS samples analyzed on an AB SCIEX 3200 MS/MS system. Its performance was compared with two commercially available newborn screening kits, MassChrom® and ClinSpot®, using clinical DBS specimens. Analytical performance was assessed according to relevant Clinical and Laboratory Standards Institute (CLSI) guidelines, including accuracy, precision, and linearity.Results: The PH-NBS-D assay showed good analytical performance, with recovery rates ranging from 91% to 115%. Repeatability CVs ranged from 4.1% to 12.9%, between-day variation from 0.0% to 8.6%, and total precision CVs from 7.1% to 25.7%. Linearity was excellent across the evaluated concentration ranges, with R² values above 0.99. The PHNBS-D assay showed comparable performance to the two commercial kits. In clinical samples, percentage deviations remained within the predefined acceptance limits (±30%), and Bland–Altman analysis showed no significant systematic bias, indicating good agreement between the methods.Conclusions: The PH-NBS-D MS/MS assay showed satisfactory analytical performance and good agreement with the evaluated commercial newborn screening assays. These findings support its potential use for measuring amino acids and acylcarnitines in DBS specimens and for further evaluation in routine newborn screening.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Acylcarnitine</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Humans</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Inborn metabolic disorders</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Infant</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Newborn</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Newborn screening</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Tandem mass spectrometry</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.ajmb.org/article_254879_fab9a7dcd9d52b19cd472721c5a7e231.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Avicenna Research Institute</PublisherName>
				<JournalTitle>Avicenna Journal of Medical Biotechnology</JournalTitle>
				<Issn>2008-2835</Issn>
				<Volume>18</Volume>
				<Issue>4</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>10</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Hydrophobic Surgical Mask Based on Sputtered Amorphous Carbon Embedded Silve Nanocluster (SAC-Ag) Film</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>353</FirstPage>
			<LastPage>356</LastPage>
			<ELocationID EIdType="pii">254822</ELocationID>
			
<ELocationID EIdType="doi">10.18502/ajmb.v18i4.22932</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Elham</FirstName>
					<LastName>Mohagheghpour</LastName>
<Affiliation>Radiation Applications Research School, Nuclear Science and Technology Research Institute, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Leila</FirstName>
					<LastName>Farzin</LastName>
<Affiliation>Radiation Applications Research School, Nuclear Science and Technology Research Institute, Tehran, Iran</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2025</Year>
					<Month>12</Month>
					<Day>18</Day>
				</PubDate>
			</History>
		    <Abstract>The COVID-19 virus transmits via contaminated surfaces or respiratory droplets. Masks reduce infection risk by blocking virus-containing droplets from sneezing and talking. However, commercial surgical masks are made of low-melting-point polymers, limiting advanced coating techniques. This report presents a novel low-temperature coating method using Ion Beam Sputtering Deposition (IBSD) to apply an Amorphous Carbon-embedded silver nanocluster (SAC-Ag) film onto surgical masks. This coating significantly enhances surface hydrophobicity while preserving the polymeric substrate morphology during deposition. Improved hydrophobicity was demonstrated by a water contact angle of 136°±2.4°, indicating enhanced droplet repellence and reduced droplet adhesion on the coated surface. Additionally, the silver nanoclusters may provide antimicrobial benefits as reported in previous studies; however, antimicrobial performance was not experimentally evaluated in this work.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Coated materials</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">COVID-19</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Hydrophobicity</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Mask</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Silver</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.ajmb.org/article_254822_815a643336a6aeaaa8c33c2b1b2c9ed4.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
